Simcere Pharmaceutical Group (HKSE:02096) EV-to-Revenue : 1.98 (As of May. 23, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Simcere Pharmaceutical Group's enterprise value is HK$14,289 Mil. Simcere Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$7,227 Mil. Therefore, Simcere Pharmaceutical Group's EV-to-Revenue for today is 1.98.

The historical rank and industry rank for Simcere Pharmaceutical Group's EV-to-Revenue or its related term are showing as below:

HKSE:02096' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.76 Med: 3.7 Max: 6.78
Current: 1.97

During the past 7 years, the highest EV-to-Revenue of Simcere Pharmaceutical Group was 6.78. The lowest was 1.76. And the median was 3.70.

HKSE:02096's EV-to-Revenue is ranked better than
57.6% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.325 vs HKSE:02096: 1.97

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-23), Simcere Pharmaceutical Group's stock price is HK$5.85. Simcere Pharmaceutical Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.77. Therefore, Simcere Pharmaceutical Group's PS Ratio for today is 2.12.

Simcere Pharmaceutical Group EV-to-Revenue Historical Data

The historical data trend for Simcere Pharmaceutical Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group EV-to-Revenue Chart

Simcere Pharmaceutical Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

4.41

3.79

4.20

2.35

Simcere Pharmaceutical Group Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial							3.79	-	4.20	-	2.35

Competitive Comparison of Simcere Pharmaceutical Group's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Simcere Pharmaceutical Group's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's EV-to-Revenue falls into.

Simcere Pharmaceutical Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Simcere Pharmaceutical Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	14289.158	/	7227.483
	=	1.98

Simcere Pharmaceutical Group's current Enterprise Value is HK$14,289 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$7,227 Mil.

Simcere Pharmaceutical Group (HKSE:02096) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Simcere Pharmaceutical Group's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	5.85	/	2.765
	=	2.12

Simcere Pharmaceutical Group's share price for today is HK$5.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.77.

Simcere Pharmaceutical Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group (HKSE:02096) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » EV-to-Revenue

Traded in Other Exchanges

S2P:Germany

Address

No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042

Website

https://www.simcere.com

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines